Generic Name: Atorvastatin Calcium
Class: HMG-CoA Reductase Inhibitors
VA Class: CV350
Molecular Formula: (C33H34FN2O5)2 • Ca • H2O
CAS Number: 134523-03-8

Introduction

Antilipemic agent; hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (i.e., statin).1 18

Uses for Lipitor

Prevention of Cardiovascular Events

Adjunct to nondrug therapies (e.g., dietary management) in patients without clinical evidence of CHD who have multiple risk factors (e.g., age, smoking, hypertension, low HDL-cholesterol concentrations, family history of early CHD) to reduce the risk of MI, stroke, or angina and the risk of undergoing revascularization procedures.1

Adjunct to nondrug therapies (e.g., dietary management) in patients without clinical evidence of CHD who have type 2 diabetes mellitus and multiple risk factors (e.g., retinopathy, albuminuria, smoking, hypertension) to reduce the risk of MI or stroke.1

Adjunct to nondrug therapies (e.g., dietary management) in patients with clinical evidence of CHD to reduce the risk of nonfatal MI, fatal and nonfatal stroke, angina, or hospitalization for CHF, and the risk of undergoing revascularization procedures.1

Has been used in patients with CHD to slow the progression of coronary atherosclerosis.67

Intensive antilipemic therapy (atorvastatin 80 mg daily) shown to be more effective than moderate antilipemic therapy (pravastatin 40 mg daily) in reducing the risk of cardiovascular events in patients hospitalized for acute coronary syndrome (16% reduction in composite risk of death or major cardiovascular events for atorvastatin compared with pravastatin regimen).66 Intensive antilipemic therapy also more effective in slowing progression of coronary atherosclerosis in patients with CHD.67

Slideshow: View Frightful (But Dead Serious) Drug Side Effects

May use in fixed combination with amlodipine when treatment with both atorvastatin (for prevention of cardiovascular events) and amlodipine (for hypertension and/or CAD) is appropriate.65

Dyslipidemias

Adjunct to nondrug therapies (e.g., dietary management) in adults to decrease elevated serum total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the management of primary hypercholesterolemia (heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIa or IIb).1 May use in combination with ezetimibe for additive antilipemic effects.64

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in the management of heterozygous familial hypercholesterolemia in boys and postmenarchal girls 10–17 years of age who, despite an adequate trial of dietary management, have a serum LDL-cholesterol concentration of ≥190 mg/dL or a serum LDL-cholesterol concentration of ≥160 mg/dL and either a family history of premature cardiovascular disease or ≥2 other cardiovascular risk factors.1

Adjunct to nondrug therapies (e.g., dietary management) for the management of primary dysbetalipoproteinemia (Fredrickson type III).1

Adjunct to nondrug therapies (e.g., dietary management) for the management of elevated serum triglyceride concentrations (Fredrickson type IV).1

Reduction of elevated serum total and LDL-cholesterol concentrations in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or when such therapies are not available.1 May use in combination with ezetimibe for additive antilipemic effects.64

Has reduced total and LDL-cholesterol concentrations in patients with hypercholesterolemia associated with or exacerbated by renal transplantation 8 38 39 undergoing use of protease inhibitors.21 37

Has reduced total and LDL-cholesterol concentrations in hypercholesterolemic patients undergoing peritoneal dialysis.34

May use in fixed combination with amlodipine when treatment with both atorvastatin (for dyslipidemias) and amlodipine (for hypertension and/or CAD) is appropriate.65

Lipitor Dosage and Administration

General

  • Patients should be placed on a standard lipid-lowering diet before initiation of atorvastatin therapy and should remain on this diet during treatment with the drug.1 60 63 In patients with CHD or multiple risk factors for CHD, initiate atorvastatin therapy simultaneously with dietary therapy.1

Monitoring during Antilipemic Therapy

  • Monitor lipoprotein concentrations periodically to ensure that target LDL-cholesterol goals are achieved and maintained at <100 mg/dL (optional goal: <70 mg/dL) for patients with CHD or CHD risk equivalents; <130 mg/dL (optional goal: <100 mg/dL) for patients with ≥2 risk factors and 10-year risk of 10–20%; <130 mg/dL for patients with ≥2 risk factors and 10-year risk <10%; or <160 mg/dL for patients with 0–1 risk factor.

Administration

Oral Administration

Administer orally at any time of day without regard to meals.1 7

Dosage

Available as atorvastatin calcium; dosage expressed in terms of atorvastatin.1 65

Pediatric Patients

Dyslipidemias
Heterozygous Familial Hypercholesterolemia
Oral

Children 10–17 years of age: Initially, 10 mg once daily.1

Adjust dosage at intervals of ≥4 weeks until the desired effect on lipoprotein concentrations is observed or a daily dosage of 20 mg is reached.1

Adults

Prevention of Cardiovascular Events or Management of Dyslipidemias
Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) or Mixed Dyslipidemia
Oral

Initially, 10 or 20 mg once daily.1

Patients who require reductions of >45% in LDL-cholesterol concentration: May initiate therapy with 40 mg once daily.1

Determine serum lipoprotein concentrations within 2–4 weeks after initiating and/or titrating therapy and adjust dosage accordingly.1 Usual maintenance dosage is 10–80 mg once daily.1

Homozygous Familial Hypercholesterolemia
Oral

10–80 mg once daily.1

Atorvastatin/Amlodipine Fixed-combination Tablets (Caduet)
Oral

Patients currently receiving atorvastatin in combination with amlodipine: Use fixed combination as a substitute for the individually titrated drugs.65 Can switch to the fixed-combination preparation containing corresponding individual doses of atorvastatin and amlodipine; alternatively, can increase the dosage of one or both components for additional antihypertensive, antianginal, and/or antilipemic effects.65

Patients currently receiving either atorvastatin or amlodipine: Use fixed combination to provide additional therapy.65 Select initial dosage of the fixed combination based on current dosage of the component being used and the recommended initial dosage for the added monotherapy.65

Patients currently receiving neither atorvastatin nor amlodipine: Use fixed combination to initiate treatment in patients requiring therapy for dyslipidemias and hypertension and/or angina.65 Select initial dosage of fixed combination based on recommended dosages of the individual components.65

Prescribing Limits

Pediatric Patients

Dyslipidemias
Oral

Children 10–17 years of age: Maximum 20 mg daily.1

Special Populations

Hepatic Impairment

No specific dosage recommendations.1 (See Hepatic Impairment under Cautions and see Special Populations under Pharmacokinetics.)

Renal Impairment

Dosage modification not required.1

Geriatric Patients

No specific dosage recommendations; however, use with caution.1 (See Geriatric Use under Cautions.)

Cautions for Lipitor

Contraindications

  • Active liver disease, including unexplained, persistent elevations of serum aminotransferases.1

  • Pregnancy or lactation.1 Administer to women of childbearing age only when they are highly unlikely to conceive and have been informed of the potential hazards.1

  • Known hypersensitivity to atorvastatin or any ingredient in the formulation.1

Warnings/Precautions

Fetal/Neonatal Morbidity and Mortality

Suppression of cholesterol biosynthesis by atorvastatin could cause fetal harm.1 Congenital anomalies following intrauterine exposure to statins reported rarely.1

Administer to women of childbearing age only when they are highly unlikely to conceive and have been informed of the potential hazards.1 (See Advice to Patients.) If the patient becomes pregnant while taking the drug, immediately discontinue therapy and apprise patient of the potential fetal hazard and the lack of known clinical benefit with continued use during pregnancy.1

Musculoskeletal Effects

Myopathy (defined as muscle pain or weakness in conjunction with CK [CPK] concentration increases >10 times the ULN) reported occasionally.1

Rhabdomyolysis with acute renal failure secondary to myoglobinuria reported rarely.1

Risk of myopathy or rhabdomyolysis increased in geriatric patients (≥65 years of age) and in patients with uncontrolled hypothyroidism or renal impairment.1

Certain drug or food interactions also may increase risk of myopathy and/or rhabdomyolysis.1 (See Interactions.)

May consider periodic monitoring of CK concentrations; however, there is no assurance that such monitoring will prevent severe myopathy.1

Consider myopathy in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked increases in CK concentrations.1

Discontinue therapy if serum CK concentrations become markedly elevated or if myopathy is diagnosed or suspected.1

Temporarily withhold or discontinue therapy in any patient experiencing an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; uncontrolled seizures).1

Hepatic Effects

Increases in serum aminotransferase (AST, ALT) concentrations reported.1 Concentrations returned to or near pretreatment levels following dosage reduction or therapy interruption or discontinuance.1 Not associated with jaundice or other clinical manifestations.1

Fatal and nonfatal hepatic failure reported rarely.1

Perform liver function tests before initiation of therapy and as clinically indicated (e.g., presence of manifestations suggestive of liver damage201 ).1 Although manufacturer previously recommended more frequent monitoring,76 FDA concluded that serious statin-related liver injury is rare and unpredictable, and that routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing serious liver injury.200

If serious liver injury with clinical manifestations and/or hyperbilirubinemia or jaundice occurs, promptly interrupt atorvastatin therapy.1 If an alternate etiology is not found, do not restart atorvastatin.1

Also see Hepatic Impairment under Cautions.

Hyperglycemic Effects

Increases in HbA1c and fasting serum glucose concentrations reported.1 200 Possible increased risk of developing diabetes.200 May need to monitor glucose concentrations following initiation of statin therapy.201

FDA states that cardiovascular benefits of statins outweigh these small increased risks.200

Endogenous Steroid Production

Statins interfere with cholesterol synthesis and theoretically may blunt adrenal and/or gonadal steroid production.1

No effects on basal plasma cortisol concentration or adrenal reserve observed with atorvastatin.1 Effects on male fertility or on pituitary-gonadal axis in premenopausal women not fully established.1

Caution advised if a statin or another antilipemic agent is used concomitantly with drugs that may decrease concentrations or activity of endogenous steroid hormones (e.g. ketoconazole, spironolactone, cimetidine).1

Cognitive Impairment

Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) reported rarely.1

Generally nonserious and reversible, with variable times to symptom onset (1 day to years) and resolution (median of 3 weeks following discontinuance of therapy).1 200 Not associated with fixed or progressive dementia (e.g., Alzheimer’s disease) or clinically important cognitive decline.200 Not associated with any specific statin, patient's age, statin dosage, or concomitant drug therapy.200

FDA states that cardiovascular benefits of statins outweigh the small increased risk of cognitive impairment.200

If manifestations consistent with cognitive impairment occur, National Lipid Association (NLA) statin safety assessment task force recommends evaluating and managing patients appropriately.202

Use in Patients with Recent Stroke or TIA

In hypercholesterolemic patients without clinically evident CHD who had a stroke or TIA within the past 1–6 months, long-term (median of 4.9 years) therapy with high-dose atorvastatin (80 mg daily) associated with higher incidence of hemorrhagic stroke compared with placebo.1 73 Risk is increased in patients with history of hemorrhagic or lacunar stroke.1 75

Increases in aminotransferase or CK concentrations (≥3 or >10 times the ULN, respectively) reported more frequently in such patients receiving high-dose atorvastatin compared with placebo.1 Diabetes also reported more frequently in such patients receiving high-dose atorvastatin.1

Role as Adjunct Therapy

Prior to institution of antilipemic therapy, vigorously attempt to control serum cholesterol by appropriate dietary regimens, weight reduction, exercise, and treatment of any underlying disorder that might be the cause of lipid abnormality.1

Use of Fixed Combinations

When used in fixed combination with amlodipine, consider cautions, precautions, contraindications, and interactions associated with amlodipine.65

Specific Populations

Pregnancy

Category X.1 65 (See Contraindications and also see Fetal/Neonatal Morbidity and Mortality, under Cautions.)

Lactation

Distributed into milk in rats; may distribute into milk in humans.1 Use is contraindicated in nursing women; women who require atorvastatin therapy should not breast-feed their infants.1

Pediatric Use

Safety and efficacy not established in prepubertal children or in children <10 years of age.1 Advise adolescent girls to use effective and appropriate contraceptive methods during therapy to reduce the likelihood of unintended pregnancy.1

Safety and efficacy of atorvastatin in fixed combination with amlodipine not established in children.65

Geriatric Use

No overall differences in efficacy or safety relative to younger adults, but increased sensitivity cannot be ruled out.1 (See Special Populations under Pharmacokinetics.)

Use with caution, since age ≥65 years is a predisposing factor for myopathy, use with caution in geriatric patients.1

Safety and efficacy of atorvastatin in fixed combination with amlodipine not established in geriatric patients.65

Hepatic Impairment

Use with caution in patients who consume substantial amounts of alcohol and/or have a history of liver disease.1

Contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase concentrations.1

Renal Impairment

Dosage modification not necessary in patients with renal impairment.1 However, monitor more closely for adverse musculoskeletal effects, since history of renal impairment may be a risk factor for development of rhabdomyolysis.1

Safety and efficacy not established in patients with end-stage renal disease (ESRD); hemodialysis not expected to substantially enhance clearance since atorvastatin is extensively bound to plasma proteins.1

Common Adverse Effects

Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain.1

Interactions for Lipitor

Metabolized by CYP3A4; does not inhibit CYP3A4.1

When used in fixed combination with amlodipine, consider interactions associated with amlodipine.65 No formal drug interaction studies to date with fixed-combination preparation.65

Drugs and Foods Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP3A4: Potential pharmacokinetic interaction (variable increases in plasma atorvastatin concentrations); increased risk of myopathy or rhabdomyolysis.1 Carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly following initiation of atorvastatin therapy or an increase in dosage of either drug.1 (See Specific Drugs and Foods under Interactions.)

Inducers of CYP3A4: Potential pharmacokinetic interaction (variable reductions in plasma atorvastatin concentrations).1 (See Specific Drugs and Foods under Interactions.)

Drugs Transported by Organic Anion Transport Polypeptide 1B1

Inhibitors of organic anion transport polypeptide (OATP) 1B1: Potential pharmacokinetic interaction (increased bioavailability of atorvastatin).1

Specific Drugs and Foods

Drug

Interaction

Comments

Amlodipine

Modest increase in atorvastatin exposure1

Not clinically relevant1

Antacids

Decreased plasma atorvastatin concentrations1

Antifungals, azoles

Increased risk of myopathy or rhabdomyolysis1

Itraconazole: Increased atorvastatin peak plasma concentration and AUC1

Weigh benefits against risks of concomitant use; carefully monitor for muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Itraconazole: Use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Bile acid sequestrants

Additive cholesterol-lowering effects20

Decreased absorption of atorvastatin63

Administer statins 1 hour before or 4 hours after the bile acid sequestrant63

Colchicine

Myopathy, including rhabdomyolysis, reported1

Use concomitantly with caution1

Cyclosporine

Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Avoid concomitant use1

Digoxin

Increased plasma digoxin concentrations1

Monitor appropriately1

Efavirenz

Possible variable reductions in plasma atorvastatin concentrations1

Fibric acid derivatives (e.g., fenofibrate, gemfibrozil)

Increased risk of myopathy1

Fenofibrate: Slight increase in atorvastatin AUC72

Gemfibrozil: Increased atorvastatin AUC1

Gemfibrozil: Avoid concomitant use1

Other fibric acid derivatives (e.g., fenofibrate): Use concomitantly with caution; consider lower initial and maintenance dosages of atorvastatin; carefully monitor for muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Grapefruit juice

Increased atorvastatin peak plasma concentration and AUC; more substantial increases in atorvastatin peak plasma concentration and/or AUC following ingestion of large quantities (≥750–1200 mL daily) of grapefruit juice1

Ingestion of large quantities (>1 L daily) of grapefruit juice may increase risk of myopathy1

HCV protease inhibitors (boceprevir, telaprevir)

Telaprevir: Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Boceprevir: Carefully titrate atorvastatin dosage; do not exceed atorvastatin dosage of 20 mg daily77

Telaprevir: Avoid concomitant use1

HIV protease inhibitors

Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Weigh benefits against risks of concomitant use; carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Ritonavir-boosted darunavir, fosamprenavir or ritonavir-boosted fosamprenavir, or ritonavir-boosted saquinavir: Use concomitantly with caution; use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Lopinavir/ritonavir: Use concomitantly with caution; use lowest necessary dosage of atorvastatin1

Nelfinavir: Use concomitantly with caution; use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 40 mg daily1

Ritonavir-boosted tipranavir: Avoid concomitant use1

Macrolides (i.e., clarithromycin, erythromycin)

Clarithromycin, erythromycin: Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Weigh benefits against risks of concomitant use; carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Clarithromycin: Use concomitantly with caution; use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Erythromycin: Use concomitantly with caution; consider using lower initial and maintenance dosages of atorvastatin1

Niacin (antilipemic dosages [≥1 g daily])

Increased risk of myopathy1

Weigh benefits against risks of concomitant use1

Use concomitantly with caution; consider using lower initial and maintenance dosages of atorvastatin; carefully monitor patients for unexplained muscle pain, tenderness, or weakness, particularly during initial months of atorvastatin therapy or following an increase in dosage of either drug1

Oral contraceptives

Increased peak plasma concentrations and AUC of ethinyl estradiol and norethindrone1

Caution when selecting an oral contraceptive1

Rifampin

Variable effects on plasma atorvastatin concentrations;2 because delayed administration of atorvastatin following administration of rifampin associated with substantial reductions in plasma atorvastatin concentrations1

Administer simultaneously

Warfarin

No clinically important effect on PT1

Lipitor Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed following oral administration; undergoes extensive first-pass metabolism in the liver.1

Peak plasma concentrations attained at 1–2 hours.1

Absolute bioavailability is approximately 14%.1

Evening administration associated with a decrease in the extent of absorption;1 however, antilipemic activity remains unchanged.1

Onset

Therapeutic response usually is apparent within 2 weeks; maximal response occurs within 4 weeks.1

Food

Food decreases rate and extent of absorption but does not alter antilipemic effects.1

Special Populations

Hepatic impairment (Child-Pugh class A and B) or alcoholic liver disease: Substantially increased concentrations.1

Geriatric patients: Peak plasma concentration and AUC are 40 and 30% higher, respectively, in geriatric individuals (≥65 years of age) compared with younger adults.1

Distribution

Extent

Statins are distributed mainly to the liver.

Distributes into milk in rats; may distribute into human milk.1

Plasma Protein Binding

≥98% (principally albumin).1

Elimination

Metabolism

Extensively metabolized in the liver,1 mainly by CYP3A4,1 to active metabolites.1

Elimination Route

Excreted principally in feces; <2% of a dose excreted in urine.1

Half-life

Approximately 14 hours.1

Stability

Storage

Oral

Tablets

Atorvastatin: 20–25°C.1

Atorvastatin/amlodipine fixed combination: 25°C (may be exposed to 15–30°C).65

Actions

  • Selectively and competitively inhibits HMG-CoA reductase, causing subsequent reduction in hepatic cholesterol synthesis.1 Reduces serum concentrations of total cholesterol, LDL-cholesterol, apo B, triglycerides, VLDL-cholesterol, IDL-cholesterol, and non-HDL-cholesterol, and increases serum concentrations of HDL-cholesterol and apolipoprotein A-1.1

  • Statins may slow progression of and/or induce regression of atherosclerosis in coronary and/or carotid arteries; modulate BP in hypercholesterolemic patients with hypertension; and possess anti-inflammatory activity.

Advice to Patients

  • Importance of adhering to nondrug therapies and measures, including dietary management, weight control, physical activity, and management of potentially contributory disease (e.g., diabetes mellitus).1 63

  • Importance of periodic monitoring of lipoprotein profile to determine goal attainment.1

  • Risk of myopathy and/or rhabdomyolysis.1 Importance of patients promptly reporting any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.1

  • Risk of adverse hepatic effects.1 Importance of promptly reporting any symptoms suggestive of liver injury (e.g., fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice).1

  • Risk of nonserious, reversible cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion).1 200

  • Risk of increased glucose concentrations and development of type 2 diabetes;1 200 may need to monitor glucose concentrations following initiation of statin therapy.201

  • Importance of advising women and adolescent girls to avoid pregnancy (i.e., using effective and appropriate contraceptive methods) during therapy and informing pregnant women of risk to fetus.1

  • Importance of avoiding breast-feeding during therapy.1 If the patient has a lipid disorder and is breast-feeding, importance of contacting a clinician to discuss other antilipemic treatment options.1

  • Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Atorvastatin Calcium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

10 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

20 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

40 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

80 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

Atorvastatin Calcium Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

10 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)

Caduet

Pfizer

10 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)

Caduet

Pfizer

10 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)

Caduet

Pfizer

80 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)

Caduet

Pfizer

80 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)

Caduet

Pfizer

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Amlodipine-Atorvastatin 10-10MG Tablets (RANBAXY PHARMACEUTICALS): 30/$140.00 or 90/$395.96

Amlodipine-Atorvastatin 10-20MG Tablets (RANBAXY PHARMACEUTICALS): 30/$169.99 or 90/$479.95

Amlodipine-Atorvastatin 10-40MG Tablets (RANBAXY PHARMACEUTICALS): 30/$159.98 or 90/$459.98

Amlodipine-Atorvastatin 5-10MG Tablets (RANBAXY PHARMACEUTICALS): 30/$140.00 or 90/$395.96

Amlodipine-Atorvastatin 5-20MG Tablets (RANBAXY PHARMACEUTICALS): 30/$169.99 or 90/$479.95

Amlodipine-Atorvastatin 5-40MG Tablets (RANBAXY PHARMACEUTICALS): 30/$180.00 or 90/$479.95

Atorvastatin Calcium 10MG Tablets (WATSON LABS): 30/$99.99 or 90/$275.96

Atorvastatin Calcium 20MG Tablets (WATSON LABS): 30/$129.99 or 90/$359.98

Atorvastatin Calcium 40MG Tablets (WATSON LABS): 30/$129.99 or 90/$359.98

Atorvastatin Calcium 80MG Tablets (WATSON LABS): 30/$129.99 or 90/$359.98

Caduet 10-10MG Tablets (PFIZER U.S.): 30/$167.98 or 90/$474.95

Caduet 10-20MG Tablets (PFIZER U.S.): 30/$226.99 or 90/$654.96

Caduet 10-40MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$651.99

Caduet 10-80MG Tablets (PFIZER U.S.): 30/$227.89 or 90/$620.05

Caduet 2.5-10MG Tablets (PFIZER U.S.): 30/$162.45 or 90/$470.56

Caduet 2.5-20MG Tablets (PFIZER U.S.): 30/$226.00 or 90/$635.99

Caduet 2.5-40MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$639.99

Caduet 5-10MG Tablets (PFIZER U.S.): 30/$162.99 or 90/$458.96

Caduet 5-20MG Tablets (PFIZER U.S.): 30/$224.00 or 90/$636.95

Caduet 5-40MG Tablets (PFIZER U.S.): 30/$218.00 or 90/$621.98

Caduet 5-80MG Tablets (PFIZER U.S.): 30/$227.98 or 90/$650.96

Lipitor 10MG Tablets (PFIZER U.S.): 30/$119.99 or 90/$336.97

Lipitor 20MG Tablets (PFIZER U.S.): 30/$164.99 or 90/$478.97

Lipitor 40MG Tablets (PFIZER U.S.): 30/$166.99 or 90/$482.97

Lipitor 80MG Tablets (PFIZER U.S.): 30/$164.99 or 90/$474.97

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions February 15, 2013. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Pfizer. Lipitor (atorvastatin calcium) tablets prescribing information. New York, NY; 2012 Feb.

2. Parke-Davis. Lipitor formulary information. Morris Plains, NJ; 1997 Feb.

5. Kastelein JJP, Isaacsohn JL, Ose L et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000; 86:221-3. [IDIS 449873] [PubMed 10913488]

7. Lea AP, McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997;53(5):828-847.

8. Nawrocki J, Schwartz S, Fayad R, et al. Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM with hyperlipidemia. Paper presented at 66th Congress of the European Atherosclerosis Society. Florence, Italy; 1996.

9. McKenney JM, McCormick LS, Weiss S et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104:137-43.

10. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17:1793-9.

11. Parke-Davis, Morris Plains, NJ: Personal communication.

12. Heinonen T, Stein E, Issacsohn J, et al. Atorvastatin in the treatment of severe hypercholesterolemia. In: 66th Congress of the European Atherosclerosis Society Abstract Book: 1996 July 13-17, Florence Italy, 214. Abstract.

13. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG Co-A reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-33.

15. Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia. Atherosclerosis. 1995;115 (Suppl):S20. Abstract.

16. Bairaktari ET, Tzallas CS, Tsimihodimos VK, et al. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk. 1999;6:113-6.

17. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL-cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 1998;47(5):349-56.

18. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-C cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-82.

19. Heinonen TM, Stein F, Weiss SR, et al. The lipid lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996;18(5):853-63.

20. Heinonen TM, Schrott H, McKenney JM, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Therapeut. 1996;1(2):117-22.

21. Murillas J, Martin T, Ramos A et al. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS. 1999; 13:1424-5. [PubMed 10449305]

22. Witzum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Limbird LE, Molinoff PB et al eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:875-97.

23. McVey D, Patel H, Eminton Z et al. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. Int J Clin Pract. 1999; 53:509-13. [IDIS 484739] [PubMed 10692735]

24. Wierzbicki AS, Lumb PJ, Crook MA et al. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 1999; 53:609-11. [IDIS 439181] [PubMed 10692755]

25. Cilla DD, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36:604-9.

26. Crouse JR, Frohlich J, Ose L, et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999;83:1476-80.

27. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.

28. Raal FJ, Pilcher GJ, Veller MG et al. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999; 84:1344-6. [IDIS 440669] [PubMed 10614803]

30. Davidson MM, McKenney JM, Stein EA, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.

31. Stern R, Yang B, Horton M, et al. Renal dysfunction does not alter the pharmacokinetics or low density lipoprotein concentration reduction of atorvastatin. J Clin Pharmacol. 1997;37(9):816-9.

32. Gibson DM, Yang BB, Abel RB, et al. Effects of hepatic and renal impairment on pharmacokinetics (pk) and pharmacodynamics (pd) of atorvastatin (abstract). Pharm Res. 1996;13(suppl):428S.

33. Ginsberg HN, Goldberg IJ. Disorders of lipoprotein metabolism. In: Harrison’s principles of internal medicine. 14th ed. New York: McGraw-Hill Book Co; 1998:2138-49.

34. Hugnagel G, Michel C, Vrtovsnik F et al. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant. 2000; 15:684-8. [PubMed 10809811]

35. Waters DD. Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial. Can J Cardiol. 2000; 16(suppl A):11-3A.

36. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Therapeut. 2000; 5:27-31.

37. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1031-2.

38. Velussi M, Cernigoi AM, Tortul C et al. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia: a mid-term (9 months) treatment experience. Diab Nutr Metab. 1999; 12:407-12.

39. Paolisso G, Barbagallo M, Petrella G et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000; 150:121-7. [PubMed 10781642]

40. Raal FJ, Pappu AS, Illingworth DR et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000; 150:421-8. [PubMed 10856535]

41. American Heart Association. AHA conference report on cholesterol. Circulation. 1989; 80:715-48. [PubMed 2670320]

42. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23.

44. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1248-51.

45. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38:2071-78.

46. McKenney JM. Dyslipidemias. In: Applied therapeutics. the clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics, Inc. 1995; 9-1-9-23.

47. Muck W, Frey R, Unger S et al. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening. Int J Clin Pharmacol Ther. 2000; 38:298-303. [IDIS 448131] [PubMed 10890578]

48. American Medical Association Council on Scientific Affairs. Dietary and pharmacologic therapy for the lipid risk factors. JAMA. 1983; 250:1873-9. [IDIS 176576] [PubMed 6620484]

49. Hoeg JM, Gregg RE, Brewer HB. An approach to the management of hyperlipoproteinemia. JAMA. 1986; 255:512-21. [IDIS 209539] [PubMed 3510334]

50. National Institutes of Health Office of Medical Applications of Research. Consensus conference: lowering blood cholesterol to prevent heart disease. JAMA. 1985;25:2080-6.

51. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol. 1998;81:582-587.

52. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin, and simvastatin. J Am Coll Cardiol. 1998;32(3):665-72.

53. McCormick L, Black DM, Waters D, et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT). Am J Cardiol. 1997;80:1130-33.

54. Pitt B, Waters D, Brown WV, et al. Aggresive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341(2):70-76.

56. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-7.

57. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest. 1983;72:743-7.

58. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 1977; 46:897-930. [PubMed 197883]

59. Parke-Davis, Morris Plains, NJ: Personal communication on the HMG-CoA Reductase Inhibitors General Statement.

60. Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97. [IDIS 464555] [PubMed 11368702]

61. Schwartz GG, Olsson AG, Ezekowitz MD et al for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators. JAMA. 2001; 285:1711-8.

62. Anon. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001; 43:43-8. [PubMed 11378632]

63. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel III Report. From AHA web site .

64. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) tablets prescribing information. North Wales, PA; 2009 Jan.

65. Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets prescribing information. New York, NY; 2012 Jan.

66. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-504. [IDIS 514118] [PubMed 15007110]

67. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291: 1071-80. [IDIS 511905] [PubMed 14996776]

68. LaRosa JC, Grundy SM, Waters DD et al for the Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-35. [IDIS 531354] [PubMed 15755765]

69. Waters DD, Guyton JR, Herrington DM et al for the TNT steering committee members and investigators. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004; 93: 154-8.

70. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? N Engl J Med. 2005; 352:1483-4.

71. Deedwania P, Barter P, Carmena R et al for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368:919–28.

72. Abbott Laboratories. TriCor (fenofibrate) tablets prescribing information. North Chicago, IL; 2008 Jun.

73. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355:549-59. [PubMed 16899775]

74. Kent DM. Stroke—An equal opportunity for the initiation of statin therapy. N Engl J Med. 2006; 355:613-5. [PubMed 16899782]

75. Pfizer, New York, NY: Personal communication.

76. Parke-Davis. Lipitor (atorvastatin calcium) tablets prescribing information. New York, NY; 2007 Nov.

77. Merck & Co., Inc. Victrelis (boceprevir) capsules prescribing information. Whitehouse Station, NJ; 2012 Jul.

200. Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. Rockville, MD; 2012 Feb 28. From FDA website.

201. Food and Drug Administration. FDA expands advice on statin risks. Rockville, MD; 2012 Feb 27. From FDA website.

202. McKenney JM, Davidson MH, Jacobson TA et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97(suppl):89-94C.

Hide
(web2)